TransCode Therapeutics Announces Withdrawal of Registration Statement

December 6, 2022

https://www.globenewswire.com/news-release/2022/12/06/2568806/0/en/TransCode-Therapeutics-Announces-Withdrawal-of-Registration-Statement.html

BOSTON, Dec. 06, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ:RNAZ) (the “Company”), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that it withdrew the Registration Statement on Form S-1 it filed with the U.S. Securities and Exchange Commission on November 28, 2022, and amended on November 30, 2022. The withdrawal reflects the Company’s belief that current market conditions are not conducive for an offering on terms that would be in the best interests of the Company’s stockholders.

Read more at globenewswire.com

Related news for (RNAZ)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.